A Case of Development of Vitiligo Followed by TNF-alpha Antagonist Treatment for Rheumatoid Arthritis
Journal of Rheumatic Diseases
;
: 216-219, 2012.
Artigo
em Coreano
| WPRIM
| ID: wpr-11342
ABSTRACT
As the usage of biologics for rheumatic diseases increases, such as rheumatoid arthritis and ankylosing spondylitis, various cutaneous adverse events are also being increasingly reported. We experienced a case of development of vitiligo during a TNF-alpha antagonist therapy in a 22-year-old woman with rheumatoid arthritis. The patient was presented with vitiligo lesions on the dorsum of both hands after 1 month of treatment with etanercept. Vitiligo improved with topical tacrolimus ointment and excimer laser treatment without the discontinuation of etanercept. No clearly defined mechanism for vitiligo induced by TNF-alpha antagonist exits. However, considering that vitiligo is an autoimmune disorder, the development of this skin lesion in association with the TNF-alpha antagonist could be explained by a paradoxical induction of the autoimmune process.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Artrite Reumatoide
/
Pele
/
Espondilite Anquilosante
/
Vitiligo
/
Imunoglobulina G
/
Doenças Reumáticas
/
Fator de Necrose Tumoral alfa
/
Tacrolimo
/
Receptores do Fator de Necrose Tumoral
/
Lasers de Excimer
Limite:
Feminino
/
Humanos
Idioma:
Coreano
Revista:
Journal of Rheumatic Diseases
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS